Oxaliplatin pharmacokinetics

Kem, W., Braess, J., Bottger, B., Kaufinann, C.C., Hiddemann, W., Schleyer, E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin. Cancer Res. 5, 761-765 (1999)... 

Levi, F., Metzger, G., Massari, C., Milano, G. Oxaliplatin pharmacokinetics and chronopharma-cological aspects. Clin Pharmaeokinet 2000, 38, 1-21. 

ICP-MS has been employed, as discussed in Section 9.5, for the determination of platinum originating from cisplatin, carboplatin and oxaliplatin in human plasma ultrafiltrate. The method developed was successfully used to support pharmacokinetic studies in cancer patients treated with cisplatin, carboplatin or oxaliplatin.5 Counterfeit products on the drug market, which have important implications for pharmaceutical companies and human health, can be clarified by mass spectrometric isotope ratio measurements. For example, precise and accurate sulfur isotope measurements (a 54S) by MC-ICP-MS, were employed to study the isotope variation of pharmaceuticals and to detect to the origin of counterfeits by Clough el al.6... 

Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol, 2000, 45, 157-164. 

Morrison, J.G., White, P., McDougall, S., Firth, J.W., Woolfrey, S.G., Graham, M.A., Greenslade, D. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids application to clinical pharmacokinetic studies with oxaliplatin. J. Pharm. Biomed. Anal. 24, 1-10 (2000)... 

There are significant pharmacokinetic differences among cisplatin, carboplatin, and oxahplatin. Cisplatin is the most highly protein-bound (>90%), followed by oxaliplatin (85%) and carboplatin (24—50%). 

The further development of the third-generation platinum derivative tetraplatin (ormaplatin, trans-u, L-l,2-diaminocyclohexane tetrachloroplatinnm) has been abandoned, because drug-induced severe motor and sensory peripheral neuropathy occurred even at low cumulative doses. The high neurotoxic potential of tetraplatin may be associated with its pharmacokinetics it is rapidly metabolized to 1,2-DACH-platinnm dichloride, which was 3.8 times more nenro-toxic than oxaliplatin in a neurite ontgrowth assay (45). 

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, Ouldkaci M, Besmaine A, Dupont-Andre G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999 17(6) 1751-9. 

The pharmacokinetics of gemeitabine 800 to 1500 mg/m and its main metabolite did not appear to be affected by oxaliplatin 70 to 100 mg/m when oxaliplatin was given immediately after gemeitabine once every two weeks. ... 

Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffle P, Kayitalire L, Armand J-P, RaymondE. Phase I-II and pharmacokinetic study ofgem-citabine combined with oxaliplatin in patients widi advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol (2002) 13,1479-89. 

Luo FR, Wyrick SD, Chaney SG (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with or-maplatin following a single bolus injection in rats. Cancer Chemother Pharmacol 44 19 28 Mattern J, Kallinowski F, Herfarth C, Vohn M (1996) Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 67 20 23... 

---